(Q39549328)

English

Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity

scientific article published on 27 May 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

0 references

1 reference

based on heuristic

inferred from title

author name string

Sophie R Sierro

1

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Alena Donda

2

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Rachel Perret

3

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Philippe Guillaume

4

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Hideo Yagita

5

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Frédéric Levy

6

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Pedro Romero

7

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

language of work or name

0 references

publication date

27 May 2011

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

European Journal of Immunology

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

41

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

2217-2228

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

Efficient induction of tumor antigen-specific CD8+ memory T cells by recombinant lentivectors.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

Dendritic cell-specific antigen delivery by coronavirus vaccine vectors induces long-lasting protective antiviral and antitumor immunity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

A modified tyrosinase-related protein 2 epitope generates high-affinity tumor-specific T cells but does not mediate therapeutic efficacy in an intradermal tumor model

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

Genetic immunization with a melanocytic self-antigen linked to foreign helper sequences breaks tolerance and induces autoimmunity and tumor immunity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

Lentivector immunization stimulates potent CD8 T cell responses against melanoma self-antigen tyrosinase-related protein 1 and generates antitumor immunity in mice.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

Optimization of a self antigen for presentation of multiple epitopes in cancer immunity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

Tumor progression inhibits the induction of multifunctionality in adoptively transferred tumor-specific CD8+ T cells.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

IL-7 adjuvant treatment enhances long-term tumor-antigen-specific CD8+ T-cell responses after immunization with recombinant lentivector

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

PD-L1 has distinct functions in hematopoietic and nonhematopoietic cells in regulating T cell responses during chronic infection in mice.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

Melanoma progression despite infiltration by in vivo-primed TRP-2-specific T cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

HIV-1 lentiviral vector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

Tubulovesicular structures within vesicular stomatitis virus G protein-pseudotyped lentiviral vector preparations carry DNA and stimulate antiviral responses via Toll-like receptor 9.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

Differential association of programmed death-1 and CD57 with ex vivo survival of CD8+ T cells in HIV infection

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

Cyclophosphamide induces dynamic alterations in the host microenvironments resulting in a Flt3 ligand-dependent expansion of dendritic cells.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

Targeting dendritic cell signaling to regulate the response to immunization

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

Astaxanthin intervention ameliorates cyclophosphamide-induced oxidative stress, DNA damage and early hepatocarcinogenesis in rat: role of Nrf2, p53, p38 and phase-II enzymes

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

Final antigenic Melan-A peptides produced directly by the proteasomes are preferentially selected for presentation by HLA-A*0201 in melanoma cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

Cutting edge: rapid in vivo killing by memory CD8 T cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

21 January 2018

New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

7 January 2021

based on heuristic

inferred from DOI database lookup

Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

7 January 2021

based on heuristic

inferred from DOI database lookup

Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

7 January 2021

based on heuristic

inferred from DOI database lookup

Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201041235

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/EJI.201041235

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39549328&oldid=1837685073"